Phosphatidylinositol 3‐kinase gamma (PI3Kγ) inhibitor can sensitize the anti‐programmed death‐1/programmed death ligand‐1 (anti‐PD‐1/PD‐L1) response in ovarian cancer by modulating the PI3Kγ‐AKT‐NF‐κB pathway to remodel tumor immune microenvironment as an activated status, along with downregulating the expression of PD‐L1. Here, AKT1 is linked to neoplasm.